MARIPOSA-2: Is the treatment worse than the disease?

Passaro et al. 1 Passaro A. Wang J. Wang Y. Lee S.H. Melosky B. Shih J.Y. Wang J. Azuma K. Juan-Vidal O. Cobo M. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study. Ann. Oncol. 2023; Abstract Full Text Full Text PDF Scopus (0) Google Scholar demonstrated in EGFR+ NSCLC post-1L osimertinib both “quad” (lazertinib [L] + amivantamab [A] + chemotherapy [CP]) and “triplet” (ACP) regimens achieved improved median progression-free survival over CP. Nonetheless, a high incidence of adverse events requiring dose modifications may limit adaptation of the triplet and quad MARIPOSA-2 regimens. Passaro et al. 1 Passaro A. Wang J. Wang Y. Lee S.H. Melosky B. Shih J.Y. Wang J. Azuma K. Juan-Vidal O. Cobo M. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study. Ann. Oncol. 2023; Abstract Full Text Full Text PDF Scopus (0) Google Scholar demonstrated in EGFR+ NSCLC post-1L osimertinib both “quad” (lazertinib [L] + amivantamab [A] + chemotherapy [CP]) and “triplet” (ACP) regimens achieved improved median progression-free survival over CP. Nonetheless, a high incidence of adverse events requiring dose modifications may limit adaptation of the triplet and quad MARIPOSA-2 regimens.